1. Newsroom
  2. Impact Report 2020
Menu
洞见 21.05.2021

Impact Report 2020

Impact Report 2020

UBP is issuing its Impact Report 2020 on last year’s developments for its impact platform, including the launch of an emerging markets strategy.


Impact investing is evolving rapidly. Each year, we think that the current rate of development will be impossible to match, only to be surprised by even faster growth. The year 2020 was no exception. Indeed, it was the year when sustainable investing came of age. It also was the year when the UBP Impact team extended its reach to emerging markets. Two key areas of development over the course of last year have been our thematic approach and the evolution of our engagement process. Biodiversity has become of primary interest to us, underscored by the launch of the Impact platform’s Biodiversity Policy in 2021 and the addition of a fourth member to UBP’s Impact Advisory Board.

Impact investing and sustainable investments are not one and the same thing. Unlike leading multinational companies, whose focus on environmental, social and governance (“ESG”) criteria often accords them high scores, impactful companies are not necessarily ESG champions. At UBP, impact investing typically starts with the identification of a powerful solution for which sustainability plays an important, but merely supporting role. What matters to us is the degree to which a company’s approach to its operations is in harmony with its products and revenue streams.

Funds

Check out our Impact Report 2020!

You can access UBP's Impact Report 2020 here:

Read the Impact Report 2020 Synopsis


延伸阅读

洞见 26.11.2021

The strong performance potential of Swiss small and mid-cap equities

The Swiss small- and mid-cap (also known as “SMID-cap”) universe offers a balanced and diversified exposure to companies with long-term value-creation potential. Active managers can create significant added value through a disciplined stock-selection process.

洞见 22.11.2021

CRISPR: the implications of gene editing

In the latest episode of UBP’s Expert series, Norman Villamin, CIO Wealth Management and Pierre Corby, Equity Analyst Healthcare, invited Dr Samarth Kulkarni, CEO of CRISPR Therapeutics, to discuss the challenges and investment opportunities offered by medical innovation, specifically in the field of gene editing.

洞见 19.11.2021

UBP Investment Outlook 2022

Embracing Change